Nemonapride (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nemonapride" in English language version.

refsWebsite

Global rank English rank

9doi.org

2^nd place

9nih.gov

4^th place

3books.google.com

3^rd place

2web.archive.org

1^st place

2who.int

195^th place

302^nd place

1kegg.jp

low place

1springer.com

274^th place

309^th place

1semanticscholar.org

11^th place

8^th place

1pmda.go.jp

6,690^th place

low place

1drugs.com

399^th place

333^rd place

books.google.com (Global: 3^rd place; English: 3^rd place)

Burke A, Marques C, Turner N, Hermann G (2018). Active Pharmaceutical Ingredients in Synthesis: Catalytic Processes in Research and Development. Wiley. p. 380. ISBN 978-3-527-34241-9. Retrieved 24 October 2024.
Schweizerischer Apotheker-Verein (2004). Index Nominum: International Drug Directory. Medpharm Scientific Publishers. p. 845. ISBN 978-3-88763-101-7. Retrieved 24 October 2024.
Morton IK, Hall JM (2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Netherlands. p. 191. ISBN 978-94-011-4439-1. Retrieved 24 October 2024.

doi.org (Global: 2^nd place; English: 2^nd place)

Bishara D, Taylor D (2008). "Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability". Drugs. 68 (16): 2269–2292. doi:10.2165/0003495-200868160-00002. PMID 18973393.
Kusumi I, Boku S, Takahashi Y (May 2015). "Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis". Psychiatry and Clinical Neurosciences. 69 (5). Wiley: 243–258. doi:10.1111/pcn.12242. PMID 25296946. S2CID 23102204.
MacDonald GJ, Bartolomé JM (2010). "A decade of progress in the discovery and development of 'atypical' antipsychotics". Prog Med Chem. Progress in Medicinal Chemistry. 49: 37–80. doi:10.1016/S0079-6468(10)49002-5. ISBN 978-0-12-381292-6. PMID 20855038.
Newman-Tancredi A, Kleven MS (August 2011). "Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties". Psychopharmacology (Berl). 216 (4): 451–473. doi:10.1007/s00213-011-2247-y. PMID 21394633.
Assié MB, Cosi C, Koek W (September 1997). "5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine". Eur J Pharmacol. 334 (2–3): 141–147. doi:10.1016/s0014-2999(97)01207-7. PMID 9369342.
Wilson JM, Sanyal S, Van Tol HH (June 1998). "Dopamine D2 and D4 receptor ligands: relation to antipsychotic action". Eur J Pharmacol. 351 (3): 273–286. doi:10.1016/s0014-2999(98)00312-4. PMID 9721018.
Iwanami S, Takashima M, Hirata Y, Hasegawa O, Usuda S (October 1981). "Synthesis and neuroleptic activity of benzamides. Cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide and related compounds". Journal of Medicinal Chemistry. 24 (10). American Chemical Society (ACS): 1224–1230. doi:10.1021/jm00142a019. PMID 6120234.
Harada S, Sakai T, Takasu K, Yamada K, Yamamoto Y, Tomioka K (September 2012). "General entry to asymmetric one-pot [N + 2 + n] cyclization for the synthesis of three- to seven-membered azacycloalkanes". The Journal of Organic Chemistry. 77 (17). American Chemical Society (ACS): 7212–7222. doi:10.1021/jo301495a. PMID 22894619.
Uesugi SI, Sasano Y, Matsui S, Kanoh N, Iwabuchi Y (2017). "Concise, Protecting-Group-Free Synthesis of (+)-Nemonapride via Eu(OTf)₃-Catalyzed Aminolysis of 3,4-Epoxy Alcohol". Chemical & Pharmaceutical Bulletin. 65 (1). Pharmaceutical Society of Japan: 22–24. doi:10.1248/cpb.c16-00568. PMID 28049911.

drugs.com (Global: 399^th place; English: 333^rd place)

"Nemonapride". Drugs.com. Archived from the original on 2016-03-03.

kegg.jp (Global: low place; English: low place)

"医療用医薬品 : エミレース (エミレース錠3mg 他)". KEGG (in Japanese). 18 September 2024. Retrieved 24 October 2024.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Bishara D, Taylor D (2008). "Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability". Drugs. 68 (16): 2269–2292. doi:10.2165/0003495-200868160-00002. PMID 18973393.
Kusumi I, Boku S, Takahashi Y (May 2015). "Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis". Psychiatry and Clinical Neurosciences. 69 (5). Wiley: 243–258. doi:10.1111/pcn.12242. PMID 25296946. S2CID 23102204.
MacDonald GJ, Bartolomé JM (2010). "A decade of progress in the discovery and development of 'atypical' antipsychotics". Prog Med Chem. Progress in Medicinal Chemistry. 49: 37–80. doi:10.1016/S0079-6468(10)49002-5. ISBN 978-0-12-381292-6. PMID 20855038.
Newman-Tancredi A, Kleven MS (August 2011). "Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties". Psychopharmacology (Berl). 216 (4): 451–473. doi:10.1007/s00213-011-2247-y. PMID 21394633.
Assié MB, Cosi C, Koek W (September 1997). "5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine". Eur J Pharmacol. 334 (2–3): 141–147. doi:10.1016/s0014-2999(97)01207-7. PMID 9369342.
Wilson JM, Sanyal S, Van Tol HH (June 1998). "Dopamine D2 and D4 receptor ligands: relation to antipsychotic action". Eur J Pharmacol. 351 (3): 273–286. doi:10.1016/s0014-2999(98)00312-4. PMID 9721018.
Iwanami S, Takashima M, Hirata Y, Hasegawa O, Usuda S (October 1981). "Synthesis and neuroleptic activity of benzamides. Cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide and related compounds". Journal of Medicinal Chemistry. 24 (10). American Chemical Society (ACS): 1224–1230. doi:10.1021/jm00142a019. PMID 6120234.
Harada S, Sakai T, Takasu K, Yamada K, Yamamoto Y, Tomioka K (September 2012). "General entry to asymmetric one-pot [N + 2 + n] cyclization for the synthesis of three- to seven-membered azacycloalkanes". The Journal of Organic Chemistry. 77 (17). American Chemical Society (ACS): 7212–7222. doi:10.1021/jo301495a. PMID 22894619.
Uesugi SI, Sasano Y, Matsui S, Kanoh N, Iwabuchi Y (2017). "Concise, Protecting-Group-Free Synthesis of (+)-Nemonapride via Eu(OTf)₃-Catalyzed Aminolysis of 3,4-Epoxy Alcohol". Chemical & Pharmaceutical Bulletin. 65 (1). Pharmaceutical Society of Japan: 22–24. doi:10.1248/cpb.c16-00568. PMID 28049911.

pmda.go.jp (Global: 6,690^th place; English: low place)

"Pharmaceuticals and Medical Devices Safety Information No. 265" (PDF). Pharmaceuticals and Medical Devices Agency. January 2010. Archived from the original (PDF) on 26 July 2022. Retrieved 26 July 2022.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Kusumi I, Boku S, Takahashi Y (May 2015). "Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis". Psychiatry and Clinical Neurosciences. 69 (5). Wiley: 243–258. doi:10.1111/pcn.12242. PMID 25296946. S2CID 23102204.

springer.com (Global: 274^th place; English: 309^th place)

adisinsight.springer.com

"Nemonapride". AdisInsight. 6 June 2007. Retrieved 24 October 2024.

web.archive.org (Global: 1^st place; English: 1^st place)

"Pharmaceuticals and Medical Devices Safety Information No. 265" (PDF). Pharmaceuticals and Medical Devices Agency. January 2010. Archived from the original (PDF) on 26 July 2022. Retrieved 26 July 2022.
"Nemonapride". Drugs.com. Archived from the original on 2016-03-03.

who.int (Global: 195^th place; English: 302^nd place)

cdn.who.int

"International Nonproprietary Names for Pharmaceutical Substances" (PDF). WHO Drug Information. 5 (3). 1991.

iris.who.int

"-pride: sulpiride derivatives and analogues" (PDF). Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. World Health Organization (WHO). 2024.

Nemonapride (English Wikipedia)

books.google.com (Global: 3rd place; English: 3rd place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 399th place; English: 333rd place)